Nusayba Bagegni, MD

Nusayba Bagegni, MD, discusses the prevalence of interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Nusayba Bagegni, MD, discusses updated efficacy and biomarker data from the phase 2 APT and ATEMPT trials in early-stage HER2-positive breast cancer.

Nusayba Bagegni, MD, discusses the safety profile of ado-trastuzumab emtansine in early-stage HER2-positive breast cancer.